Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

This clinical trial program provides expanded access to everolimus, an mTOR inhibitor, for a single patient with uterine sarcoma. Eligibility criteria are specific to the individual patient's medical condition and history. The intervention involves administering everolimus to potentially manage the patient's sarcoma, focusing on safety and efficacy in this context.

Patient Parameters